Pharmaids Pharmaceuticals Limited has announced the reconstitution of its Board Committees through a circular resolution passed on January 05, 2026. The pharmaceutical company informed the stock exchanges about these governance changes, which will take effect from January 06, 2026, in compliance with regulatory requirements.

Board Committee Restructuring

The company's Board of Directors approved the reconstitution of two key committees as part of its governance framework. This restructuring demonstrates the company's commitment to maintaining robust corporate governance standards and ensuring effective oversight mechanisms.

Audit Committee Composition

The reconstituted Audit Committee features a comprehensive structure with four members, maintaining a strong independent director presence:

The Audit Committee maintains its critical role in overseeing financial reporting, internal controls, and audit processes, with three independent directors ensuring objective oversight.

Nomination & Remuneration Committee Structure

The Nomination & Remuneration Committee has been reconstituted with three independent directors, ensuring complete independence in key personnel and compensation decisions:

This committee structure aligns with best practices in corporate governance, with Mr. Methuku Nagesh taking the leadership role as Chairman.

Regulatory Compliance

The reconstitution has been undertaken pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated these changes to BSE Limited, ensuring full transparency and regulatory compliance. The circular resolution mechanism demonstrates efficient decision-making processes within the company's governance framework.

Pharmaids Pharmaceuticals Limited has announced a key leadership change with the resignation of Dr. Sidde Gowda from his position as Vice President-Operations. The resignation was submitted on December 10, 2025, and takes effect from the close of business hours on the same date.

Resignation Details

The company has filed the mandatory disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure provides comprehensive information about the senior management personnel change.

Reason for Resignation

According to the official disclosure, Dr. Sidde Gowda has tendered his resignation due to personal reasons and pre-occupation with other commitments. In his resignation letter addressed to the Board of Directors, Dr. Gowda confirmed that there are no other material reasons for his resignation beyond the stated personal commitments.

Regulatory Compliance

Pharmaids Pharmaceuticals Limited has ensured full compliance with regulatory requirements by filing the necessary disclosures with BSE Limited. The company's filing includes all details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated November 11, 2024.

Company Information

Pharmaids Pharmaceuticals Limited operates from its registered office at Unit 201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013. The company secretary and compliance officer, Prasanna Subramanya Bhat, signed the regulatory disclosure documents.

Dr. Gowda expressed his sincere gratitude to the Board of Directors and extended his best wishes for the company's future in his resignation letter. The departure represents a change in the company's senior management structure as it continues its operations in the pharmaceutical sector.